Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Lyka Labs
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 22.24 | 22.88 | 27.99 | 32.56 | 27.77 | 30.11 | 41.16 | 33.80 | 33.43 | 33.03 | 36.66 | 30.73 | 28.03 |
| Expenses + | 18.94 | 20.24 | 23.82 | 25.69 | 25.75 | 26.40 | 36.21 | 28.61 | 29.35 | 29.35 | 39.20 | 29.08 | 34.48 |
| Operating Profit | 3.30 | 2.64 | 4.17 | 6.87 | 2.02 | 3.71 | 4.95 | 5.19 | 4.08 | 3.68 | -2.54 | 1.65 | -6.45 |
| OPM % | 14.84% | 11.54% | 14.90% | 21.10% | 7.27% | 12.32% | 12.03% | 15.36% | 12.20% | 11.14% | -6.93% | 5.37% | -23.01% |
| Other Income + | 0.02 | 0.38 | -0.18 | 0.54 | 0.32 | 0.56 | 0.03 | 0.83 | 0.82 | 0.63 | 1.09 | 1.16 | 0.61 |
| Interest | 2.85 | 1.35 | 1.19 | 1.28 | 1.07 | 0.65 | 0.54 | 0.61 | 0.47 | 0.85 | 0.79 | 0.82 | 0.70 |
| Depreciation | 3.47 | 3.47 | 3.59 | 2.84 | 2.90 | 1.76 | 1.76 | 1.83 | 1.42 | 2.11 | 2.15 | 2.15 | 2.04 |
| Profit before tax | -3.00 | -1.80 | -0.79 | 3.29 | -1.63 | 1.86 | 2.68 | 3.58 | 3.01 | 1.35 | -4.39 | -0.16 | -8.58 |
| Tax % | 0.00% | 7.22% | -22.78% | 38.60% | 28.22% | 30.65% | 28.36% | 24.30% | 32.89% | 26.67% | -26.65% | -6.25% | -6.06% |
| Net Profit + | -3.01 | -1.85 | -0.49 | 1.78 | -2.09 | 1.29 | 1.91 | 2.70 | 2.03 | 0.99 | -3.22 | -0.15 | -8.07 |
| EPS in Rs | -0.98 | -0.56 | -0.15 | 0.54 | -0.63 | 0.40 | 0.59 | 0.76 | 0.50 | 0.26 | -0.94 | 0.00 | -2.13 |
Financials of Lyka Labs
Annual income statement trend
| Jun 2015 | Mar 2016 9m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 166 | 130 | 110 | 60 | 71 | 61 | 86 | 194 | 93 | 111 | 138 | 128 |
| Expenses + | 139 | 110 | 87 | 63 | 73 | 65 | 67 | 93 | 76 | 95 | 121 | 132 |
| Operating Profit | 28 | 20 | 23 | -4 | -2 | -4 | 20 | 101 | 17 | 16 | 18 | -4 |
| OPM % | 17% | 16% | 21% | -6% | -3% | -6% | 23% | 52% | 18% | 14% | 13% | -3% |
| Other Income + | 4 | 8 | -2 | 4 | 1 | -30 | 0 | -4 | -4 | 1 | 2 | 4 |
| Interest | 24 | 15 | 19 | 10 | 7 | 20 | 26 | 20 | 12 | 5 | 2 | 3 |
| Depreciation | 11 | 9 | 10 | 11 | 7 | 8 | 8 | 17 | 14 | 13 | 7 | 8 |
| Profit before tax | -3 | 4 | -8 | -20 | -15 | -62 | -14 | 59 | -13 | -1 | 11 | -12 |
| Tax % | 31% | -5% | -19% | -5% | -59% | 1% | -29% | 35% | -0% | 182% | 29% | -11% |
| Net Profit + | -5 | 4 | -7 | -19 | -6 | -63 | -10 | 38 | -13 | -3 | 8 | -10 |
| EPS in Rs | -2.29 | 1.67 | -2.51 | -6.14 | -1.97 | -21.10 | -4.03 | 13.59 | -4.30 | -0.75 | 2.24 | -2.81 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Lyka Labs
Capital structure and asset base
| Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 22 | 22 | 22 | 28 | 28 | 29 | 29 | 29 | 31 | 33 | 36 | 36 |
| Reserves | 20 | 22 | 16 | 21 | 15 | -43 | -54 | -15 | 15 | 35 | 68 | 57 |
| Borrowings + | 137 | 121 | 126 | 113 | 96 | 141 | 163 | 130 | 75 | 59 | 39 | 49 |
| Other Liabilities + | 100 | 77 | 88 | 67 | 76 | 73 | 52 | 42 | 31 | 30 | 33 | 33 |
| Total Liabilities | 279 | 242 | 252 | 229 | 216 | 200 | 190 | 186 | 152 | 157 | 176 | 175 |
| Fixed Assets + | 122 | 104 | 133 | 116 | 108 | 105 | 98 | 94 | 68 | 58 | 85 | 87 |
| CWIP | 27 | 30 | 24 | 28 | 31 | 28 | 26 | 18 | 16 | 23 | 1 | 2 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 130 | 107 | 94 | 85 | 77 | 68 | 66 | 74 | 67 | 76 | 90 | 86 |
| Total Assets | 279 | 242 | 252 | 229 | 216 | 200 | 190 | 186 | 152 | 157 | 176 | 175 |
Financials of Lyka Labs
Operating, investing and financing cash movement
| Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 27 | 12 | 31 | 11 | 27 | 5 | 9 | 79 | 9 | 2 | 2 | 5 |
| Cash from Investing Activity + | 37 | 17 | -13 | -3 | -4 | -0 | -0 | -6 | 7 | -9 | -12 | -9 |
| Cash from Financing Activity + | -60 | -30 | -19 | -10 | -23 | 3 | -12 | -63 | -22 | 2 | 5 | 4 |
| Net Cash Flow | 4 | -1 | -0 | -3 | -1 | 9 | -3 | 10 | -5 | -6 | -5 | 0 |
| Free Cash Flow | 55 | 28 | 18 | 7 | 23 | 4 | 8 | 72 | 15 | -7 | -10 | -6 |
| CFO/OP | 97% | 60% | 143% | -318% | -1,462% | -131% | 49% | 79% | 52% | 21% | 28% | -152% |
Financials of Lyka Labs
Working capital efficiency and return ratios
| Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 124 | 121 | 97 | 125 | 75 | 48 | 37 | 35 | 79 | 89 | 114 | 100 |
| Inventory Days | 77 | 56 | 90 | 139 | 65 | 69 | 41 | 56 | 68 | 78 | 82 | 99 |
| Days Payable | 220 | 218 | 266 | 301 | 216 | 192 | 141 | 96 | 91 | 98 | 98 | 122 |
| Cash Conversion Cycle | -18 | -41 | -79 | -37 | -75 | -76 | -63 | -5 | 55 | 68 | 97 | 77 |
| Working Capital Days | -220 | -242 | -357 | -735 | -265 | -242 | -118 | -121 | -0 | 23 | 51 | 23 |
| ROCE % | 10% | 7% | 9% | -8% | -5% | -6% | 10% | 61% | 5% | 4% | 10% | -6% |
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…